Orion Oyj
ORION CORPORATION INVESTOR NEWS 15 MARCH 2021 at 13.00
Save the date – Orion’s Virtual Capital Markets Day on 26 May 2021 at 1.00 p.m. – 4.00 p.m. EEST
Orion’s virtual Capital Markets Day 2021 for investors, analysts and media will be held on 26 May 2021 at 1.00 p.m – 4.00 p.m. EEST. At the event, Orion's management will provide an update on the company's strategy, business and research & development projects.
The presentations will include updates from CEO Timo Lappalainen and other members of Orion Executive Management Board. An invitation with the agenda and the webcast registration details will be published closer to the event.
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
Tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Teva Pharmaceutical Industries Ltd16.9.2025 22:30:00 CEST | Press release
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
Society of Actuaries16.9.2025 20:46:16 CEST | Press release
Society of Actuaries Announces Planned CEO Succession in 2026
Lehman Brothers UK Capital Funding LP16.9.2025 17:53:36 CEST | Press release
Lehman Brothers UK Capital Funding LP: Notice of Proposed Interim Payment
Sampo plc16.9.2025 17:10:00 CEST | Press release
Sampo prices the issuance of new Restricted Tier 1 notes
Ringkjøbing Landbobank A/S16.9.2025 17:00:58 CEST | Pressemeddelelse
Ringkjøbing Landbobank udsteder Tier 2-kapital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom